Introduction {#Sec1}
============

Obesity and its related comorbidities impair fertility, maternal health during pregnancy, maternal obstetric outcomes, fetal outcomes, and long-term health of the offspring \[[@CR1]\]. Obesity-related comorbidities are routinely recorded before and after bariatric surgery in the UK National Bariatric Surgery Registry (NBSR) \[[@CR2], [@CR3]\]. The NBSR is a comprehensive, prospective, nationwide analysis of outcomes from bariatric surgery in the UK and Ireland. The comorbidities measured include the following: menstrual dysfunction, polycystic ovarian syndrome (PCOS), type 2 diabetes, dyslipidemia, hypertension, asthma, joint pain, functional status, gastro-esophageal reflux, and sleep disorder. Menstrual dysfunction, as defined in the registry, refers to the presence of amenorrhea, irregular periods, or menorrhagia. Functional status in this context refers to exercise tolerance, deemed impaired if the patient is unable to climb a flight of stairs without stopping.

Irregular ovulation associated with menstrual disorders, including PCOS, directly affects fertility. Insulin resistance, as a component of type 2 diabetes, may also affect fertility \[[@CR4]\], and, in addition, the maternal health, fetal outcomes, and long-term health of the offspring are impaired by dysglycemia in pregnancy \[[@CR5], [@CR6]\]. Dyslipidemia is associated with obstetric vasculopathies \[[@CR7]\]. Hypertension increases the rates of pre-eclampsia and small-for-gestational age \[[@CR8]\]. Joint pain, functional status, asthma, gastro-esophageal reflux, and sleep disorders are all common in obesity and can all be exacerbated by pregnancy, impairing the well-being of pregnant women.

Bariatric surgery reduces body weight and is an effective intervention in treating type 2 diabetes in obese patients \[[@CR9]\], but its effects on fertility and pregnancy outcomes (including maternal health during pregnancy) are not fully elucidated. It is known that weight loss achieved through lifestyle change may help improve fertility \[[@CR10]\], but there are limited data demonstrating that this is the case following BS. The official NBSR reports demonstrate an improvement in all (ten) recorded comorbidities after bariatric surgery, but no subanalyses have been made in women of reproductive age.

The aims of this study are to describe the cohort of females of reproductive age having bariatric surgery in the UK, to assess the age and ethnicity of the cohort who do access surgery, and to assess the effect of bariatric surgery on factors which underlie fertility and pregnancy outcomes.

Methods {#Sec2}
=======

Data were extracted from the UK NBSR for women aged 18--45 years. Baseline data included age, weight, height, date of operation, operation type, and presence of comorbidities. Comparative data from the overall cohort were taken from the NBSR reports 1 and 2 \[[@CR2], [@CR3]\]. Follow-up data were extracted up to 12 months after the operation and included weight and the presence of comorbidities. The NBSR records ten comorbidities before and after operation: type 2 diabetes, menstrual dysfunction, polycystic ovarian syndrome, dyslipidemia, hypertension, asthma, joint pain, functional status, gastro-esophageal reflux, and sleep disorder.

In order to compare the prevalence of each comorbidity before and after surgery, those patients with missing follow-up data were initially excluded from analysis. This follows the convention of the official NBSR reports. Sensitivity analyses were then applied, assuming that all of the patients with no follow-up had no change to their status. The prevalences were compared using the chi-squared test.

For comparison to a representative national cohort, data were extracted from the Health Survey for England (HSE), which is an annual national census. Data were collated from 2007 to 2013 inclusive. Women aged 18 to 45 with a BMI ≥40 kg/m^2^ (representing those who may be considered for bariatric surgery by NICE criteria) were selected. From this cohort, the median age was compared to the bariatric surgery cohort using Wilcoxon's test. The prevalence of type 2 diabetes and the ethnic composition of the groups were compared using a chi-squared test. All analyses were performed using the "R" statistical software.

Results {#Sec3}
=======

NBSR Cohort at the Time of Surgery {#Sec4}
----------------------------------

In total, there were 29,010 male and female patients who underwent bariatric surgery to year 2013, of whom 15,222 were women aged 18 to 45 years old (53 %). The numbers and percentages of each operation, with comparison to the overall NBSR cohort, are presented in Table [1](#Tab1){ref-type="table"}. The rates of each operation were no different between the groups. The discrepancy in the number of BPD procedures is because the female data dates back to 2003---all 18 of these operations were performed before 2007.Table 1Comparison of the type of operations performed on females of reproductive age versus the total bariatric populationFemale, aged 18--45, 2003--2013NBSR report (financial years ending 2009--2013)TotalTotal (%)Lap/endoOpenUnspec.TotalTotal (%)Lap/endoOpenUnspec.Roux-and-Y gastric bypass828154.40 %7462811812,75954.43 %11,692104918Gastric band395525.98 %3941410576424.59 %574699Sleeve gastrectomy245716.14 %244683417417.81 %41402410Gastric balloon2461.62 %245014061.73 %40204Other1260.83 %123302060.88 %19385Unspecified1280.84 %801201160.49 %50111Biliopancreatic diversion18^a^0.12 %11701^a^0.00 %001Duodenal switch11^b^0.07 %101013^b^0.06 %1210Total15,22214,23684414223,43922,1901091158^a^Note that the discrepancy between biliopancreatic diversion procedures in the overall NBSR cohort (1) and the selected cohort (18) is because our search returned all operations recorded on the register. All biliopancreatic diversions recorded in this cohort were performed from 2003 to 2007, whereas the NBSR formal report is on procedures from 2008^b^Four of the DS procedures were performed before 2008

Comparison of NBSR Patients to HSE Subjects {#Sec5}
-------------------------------------------

Collating the HSE data from 2007 to 2013 produced a total cohort of 91,649 subjects. Female subjects, aged 18--45 years old, with a recorded BMI of ≥40 kg/m^2^ totaled 384 subjects. The NBSR cohort had a median age of 38 years (IQR 32--42) and was older than the HSE cohort (median 36 years, IQR 30--41; *p* \< 0.0001, Wilcoxon test). Caucasian patients were overrepresented in the NBSR cohort (90 % of NBSR vs 84 % HSE, *p* \< 0.0001, chi-squared test, Table [2](#Tab2){ref-type="table"}). Bariatric patients were twice as likely to have type 2 diabetes as HSE subjects (14.7 % NBSR vs 7.4 % HSE, *p* \< 0.0001, chi-squared test).Table 2Comparison of the ethnic composition of the national obese population versus the surgical populationSelf-reported ethnicityUK national population females aged 18--45 years old, BMI ≥40 kg/m^2^UK females aged 18--45 years old, BMI ≥40 kg/m^2^, undergoing bariatric surgeryAfrican/Afro-Caribbean7.81 %4.53 %Asian5.73 %3.54 %Caucasian84.1 %89.9 %Other2.34 %1.99 %

Follow-Up of NBSR Cohort Following Bariatric Surgery {#Sec6}
----------------------------------------------------

There were 1107 patients with no follow-up data recorded in the registry, leaving 14,115 women with follow-up data of some kind. However, there was some inconsistency in recording of comorbidities. For instance, the number of patients with complete data for hypertension was 8668 (see Table [3](#Tab3){ref-type="table"}). Body weight and the presence or absence of comorbidities were recorded at variable time points over the 12-month postoperative period.Table 3The rate of obesity-related comorbidities at baselineComorbidityNumber of casesTotal number of patients (with complete data)PrevalenceMenstrual dysfunction2355713433.0 %PCOS1298825015.7 %Type 2 diabetes1266860914.7 %Dyslipidemia970855811.3 %Hypertension1736862320.1 %Sleep disorder985820112.0 %Impaired functional status5607839466.8 %Joint pain3707852843.5 %Asthma1742862320.2 %Gastro-esophageal reflux1560741521.0 %

The mean BMI fell in the first year postoperatively from 48.2 ± 8.3 to 37.4 ± 7.5 kg/m^2^ (*p* \< 0.001, *t* test). As this was recorded at variable time points, this is represented graphically (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Change in BMI based on the month of follow-up. The mean BMI at baseline is shown by *dot* and *error bars* at 0 months. The mean BMI recorded at each month of follow-up with *error bars*. One point per patient is shown on graph

Table [3](#Tab3){ref-type="table"} demonstrates the numbers of each comorbidity at baseline, following the exclusion of cases with missing data. Surgery led to a reduction in the numbers of each comorbidity (Table [4](#Tab4){ref-type="table"}). These findings remained valid after the sensitivity analysis (i.e., assuming no change in status to patients without follow-up). Of women with menstrual dysfunction presurgery, 12 % of patients normalized menstrual function postoperatively. Similarly, of women with PCOS preoperatively, 15 % were classed as no longer having the syndrome postoperatively. Type 2 diabetes showed the greatest improvement with 54 % of those patients who had diabetes preoperatively achieving a non-diabetic state postoperatively. The mean total number of comorbidities per patient fell from 2.36 to 0.96 (*p* \< 0.05, *t* test, Fig. [2](#Fig2){ref-type="fig"}).Table 4Improvement in the rate of obesity-related comorbidities after operationComorbidityNumber of patients with comorbidity before surgeryNumber of patients with comorbidity after surgeryProportion improved after surgery*p* valueMenstrual dysfunction2355206312.4 %*p* \< 0.0001PCOS1298110614.8 %*p* \< 0.0001Type 2 diabetes126658753.6 %*p* \< 0.0001Dyslipidemia97049748.8 %*p* \< 0.0001Hypertension1736101341.7 %*p* \< 0.0001Sleep disorder98556143.1 %*p* \< 0.0001Impaired functional status5607296747.1 %*p* \< 0.0001Joint pain3707260529.7 %*p* \< 0.0001Asthma1742122229.9 %*p* \< 0.0001Gastro-esophageal reflux1560131215.9 %*p* \< 0.0001 Fig. 2Total number of comorbidities before and after operation

Of those with a single comorbidity preoperatively, functional impairment was the most frequent (46 %). PCOS was the single comorbidity in only 4 % of these patients and menstrual dysfunction in 8 %. However, in patients with three comorbidities, menstrual dysfunction was more commonly seen: 16 % had PCOS, and 30 % had menstrual dysfunction (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Relative contribution of each comorbidity before and after operation

Discussion {#Sec7}
==========

This study demonstrates that bariatric surgery is effective at improving factors that may underlie fertility and pregnancy outcomes: body weight, type 2 diabetes, menstrual dysfunction, and PCOS. Although baseline numbers may be questioned in view of missing data, our results demonstrate improvements in the prevalence of each comorbidity, even after application of sensitivity analyses.

The meta-analyses have demonstrated that bariatric surgery improves maternal health during pregnancy (including reduction in rates of gestational diabetes \[[@CR11]--[@CR13]\] and hypertensive disorders \[[@CR11], [@CR13]\] as well as fetal benefits such as a reduction in rates of macrosomia \[[@CR11]--[@CR13]\]). Few studies have assessed the effect of bariatric surgery on menstrual disorders (including PCOS), but those available demonstrate excellent results with 70--80 % achieving normal menstruation postoperatively \[[@CR14], [@CR15]\] although sample sizes are small. Future research should include a prospective cohort design to investigate whether the improvements in the comorbidities we have demonstrated also translate to improved fertility.

The dramatic effect on weight is in keeping with data on the overall bariatric surgery population \[[@CR2]\]. A consensus view is that a reduction in body weight of 10 % is a realistic target that may help improve fertility \[[@CR16]\]. Our data show that bariatric surgery is a very effective means to achieve such a target (87.3 % of patients achieved ≥10 % weight loss).

Our data gives an intimation of the relative importance to stakeholders of the comorbidities that lead to a decision for bariatric surgery. Our data confirm that type 2 diabetes is an important trigger for bariatric surgery \[[@CR17]\] as it was overrepresented in the NBSR compared to the HSE cohort. However, only 3.5 % of patients with a single comorbidity had diabetes, suggesting that it is not necessarily taken as an indication on its own. A similar comparison to national data for PCOS and menstrual dysfunction could not be made as data in the national HSE cohort were not available for PCOS and menstrual dysfunction.

Of those with a single comorbidity, PCOS was recorded as frequently as diabetes (3.8 %) but almost twice as many had a record of menstrual dysfunction (8 %). Overall, our data demonstrate that PCOS is seen in one in six women having bariatric surgery and menstrual dysfunction is seen in almost one third of women.

The potential effect of bariatric surgery to improve fertility, whether as the primary aim of surgery or otherwise, highlights the importance of good preconception care---which is often suboptimal. In one study, 40 % of women were not aware of the recommendation to avoid pregnancy in the first 12--18 months and 30 % did not use any contraception in the 12 months after operation \[[@CR18]\]. Adherence to these recommendations may be important to avoid poor neonatal outcomes from macronutrient or micronutrient deficiencies \[[@CR19], [@CR20]\].

In order to maximize the benefits of bariatric surgery on fertility and pregnancy outcomes, the potential complications of surgery must be identified and managed appropriately. A recent retrospective analysis suggested a possible increase in neonatal mortality in mothers who underwent bariatric surgery, but this did not control for comorbidities that are likely to be important confounders \[[@CR12]\]. Nevertheless, there may be an increased risk of preterm delivery \[[@CR13]\] and small-for-gestational-age newborns \[[@CR11]--[@CR13]\] that may be related to the type of procedure: Biliopancreatic diversion is much more likely to be associated with small-for-gestational-age neonates \[[@CR19]\], while laparoscopic-assisted gastric bypass does not appear to increase the rate of small neonates \[[@CR13]\]. Note that our data demonstrate that gastric bypass is the most common operation and that biliopancreatic diversion is rarely performed. Although included in the NBSR, intragastric balloon insertion may be considered a bariatric procedure rather than surgery per se. Our data showed that while these patients have similar demographics at baseline, the reductions in BMI were less (49.8 ± 18.1 to 45.7 ± 15.0 kg/m^2^) and improvements in the comorbidities were not seen. Indeed, the rates of different operations in female patients of childbearing age closely match those in the total NBSR cohort (Table [1](#Tab1){ref-type="table"}). The similar rates for each operation raise the issue of whether this is appropriate or whether different operations should be offered to these women.

Open and timely access to bariatric surgery is important to optimize its benefits. Our data demonstrate that ethnic minorities are under-represented in the operated population, suggesting reduced access. This will require further investigation to explain possible cultural barriers and to prevent health inequalities in access to services.

The operated cohort was older than the eligible population of age-matched women. One interpretation for this is that there is a lead time from patients being eligible for surgery to having the operation. This delay is important as it falls around the key age for pregnancy success with a diminishing ovarian reserve. It has been demonstrated that before the age of 37, obesity has a significant negative impact on fertility, whereas in older women, this effect is outweighed by advancing age \[[@CR21]\]. Thus, weight loss to improve fertility should ideally occur before this age \[[@CR22]\]. That such a delay is happening may be due to delays in identification of eligible patients, delays in referral, and waiting lists for the operation itself. Clinicians should consider the benefits of operating earlier in young obese women, especially if fertility is a major concern.

The limitations of this study stem from limitations of the registry itself. Further information on preoperative childbearing history, parous state, and postoperative pregnancy would allow more direct conclusions to be drawn about the effects on fertility and pregnancy. Other data surrounding preconception care such as postoperative micronutrient supplementation or deficiency, contraceptive use, and hormonal supplementation are not recorded. It should also be noted that there is no site visit for the verification of the reported data. In the NBSR, the data is self-reported by each surgeon.

In summary, over half of all bariatric procedures are carried out on women of reproductive age. At least one in three of these women have menstrual dysfunction at baseline. Bariatric surgery improves factors that underlie fertility and pregnancy outcomes. A prospective study is required to demonstrate that this effect translates into a positive effect on pregnancy outcomes.
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